Intellectual Property partner Kevin O'Connor, Ph.D., recently participated in a roundtable titled "Getting Biosimilars to Market," discussing patent and antitrust perspectives in this developing area. Topics included commercial reasons and potential solutions for the slow uptake in U.S. markets of biosimilars, settlements between biosimilar and biologic companies, differences in future settlements between biologic antitrust litigation and brand-generic litigation, and the impact of the USPTO's revised two-step Alice/Mayo test. The roundtable participants were selected to share "their extensive experience and knowledge of the issues."

"One important distinction between small molecule generic drugs and biosimilars is a greater opportunity for the biosimilar applicant to generate innovations, for example, around new formulations or methods of manufacturing," said Kevin.

Click here to read the complete roundtable.